-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on AbbVie, Raises Price Target to $280

Benzinga·07/10/2026 13:20:26
Listen to the news
RBC Capital analyst Trung Huynh maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $260 to $280.